International and multicenter real-world study of sorafenib-treated patients with hepatocellular carcinoma under dialysis

Álvaro Díaz-González, Marco Sanduzzi-Zamparelli, L Leonardo Gomes da Fonseca, Giovan Giuseppe Di Costanzo, Rogerio Alves, Massimo Iavarone, Cassia Leal, Rodolfo Sacco, Ana María Matilla, Manuel Hernández-Guerra, Gabriel Aballay Soteras, Marcus-Alexander Wörns, Matthias Pinter, María Varela, Morten Ladekarl, Aline Lopes Chagas, Beatriz Mínguez, Juan Ignacio Arenas, Alessandro Granito, Yolanda Sánchez-TorrijosÁngela Rojas, Carlos Rodríguez de Lope, Mario Reis Alvares-da-Silva, Sonia Pascual, Lorenza Rimassa, José Luis Lledó, Carlos Huertas, Bruno Sangro, Edoardo G Giannini, Manuel Delgado, Mercedes Vergara, Christie Perelló, Alberto Lue, Margarita Sala, Adolfo Gallego, Susanna Coll, Tania Hernáez, Federico Piñero, Gustavo Pereira, Alex França, Juan Marín, Margarita Anders, Vivianne Mello, Mar Lozano, Jean Charles Nault, Josemaría Menéndez, Ignacio García Juárez, Jordi Bruix, María Reig

Research output: Contribution to journalJournal articleResearchpeer-review

1 Citation (Scopus)
Original languageEnglish
JournalLiver International
Volume40
Issue number6
Pages (from-to)1467-1476
Number of pages10
ISSN1478-3223
DOIs
Publication statusPublished - Jun 2020

Keywords

  • Hepatocellular carcinoma
  • adverse events
  • dialysis
  • safety
  • sorafenib
  • survival

Fingerprint Dive into the research topics of 'International and multicenter real-world study of sorafenib-treated patients with hepatocellular carcinoma under dialysis'. Together they form a unique fingerprint.

Cite this